BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30118336)

  • 1. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
    Kerr D; Sokol L
    Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kerr D; Zhang L; Sokol L
    Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 4. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
    Riaz W; Zhang L; Horna P; Sokol L
    Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm.
    Falcone U; Sibai H; Deotare U
    Crit Rev Oncol Hematol; 2016 Nov; 107():156-162. PubMed ID: 27823644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review.
    Kim MJ; Nasr A; Kabir B; de Nanassy J; Tang K; Menzies-Toman D; Johnston D; El Demellawy D
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):528-537. PubMed ID: 28906324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
    Wang S; Wang X; Liu M; Bai O
    Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant.
    Yun S; Chan O; Kerr D; Vincelette ND; Idrees A; Mo Q; Sweet K; Lancet JE; Kharfan-Dabaja MA; Zhang L; Sokol L
    Blood Adv; 2020 Jul; 4(14):3435-3442. PubMed ID: 32722779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
    Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
    Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
    Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
    Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
    Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
    J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Xue T; Budde LE
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.